What Is Zelboraf (Vemurafenib)? FDA Approval, Turkish Authorization, and Reimbursement

• FDA Approved: Yes (initial approval: August 17, 2011)
• Product Name: Zelboraf
• Active Ingredient: Vemurafenib
• Administration: Oral tablets
• Class: Signal transduction inhibitor, BRAF inhibitor
• Category: Targeted agent
• Manufacturer: Genentech-Roche
• Distribution in Turkey: Roche Müstahzarları Sanayi Anonim Şirketi
• Approved Cancer Indications:
  • Advanced or Metastatic Melanoma:
    • FDA-approved in BRAF-V600E mutation-positive patients.
  • Erdheim-Chester Disease (ECD):
    • FDA-approved in BRAF-V600 mutation-positive patients.

What Is Zelboraf?

Zelboraf (vemurafenib) is an oral BRAF inhibitor for BRAF-V600-mutated cancers such as advanced or metastatic melanoma and Erdheim-Chester disease. It aims to slow progression and inhibit tumor growth, particularly in BRAF mutation-positive cells.

What Is a BRAF Inhibitor?

These medicines target BRAF, a kinase in the MAPK (mitogen-activated protein kinase) pathway that supports cell growth and survival. A V600E mutation keeps BRAF continuously active, causing uncontrolled division. Inhibitors block this abnormal activity to suppress cancer cell growth.

Mechanism of Action

Vemurafenib is a small-molecule inhibitor of BRAF serine-threonine kinase, acting through the following mechanisms:

• Mutant BRAF (V600E) Inhibition:
  • It inhibits mutated BRAF kinase and blocks MAPK signaling.
  • This stops proliferation and inhibits tumor growth.
• Lack of Activity Against Wild-Type BRAF:
  • It is ineffective against wild-type, or normal, BRAF, minimizing damage to normal cells.
• Target Specificity:
  • Targeting only mutated cells reduces adverse effects in healthy cells.
• Suppression of Tumor Growth Factors:
  • It slows progression by inhibiting growth factors and cell signaling in BRAF-V600-mutated cells.

FDA (US Food and Drug Administration) Approval History

• November 6, 2017:
  • Zelboraf was approved for BRAF V600-mutated Erdheim-Chester disease.
• August 17, 2011:
  • The FDA approved Zelboraf for advanced skin cancer and an accompanying companion diagnostic test.
• May 11, 2011:
  • A new drug application for advanced skin cancer was submitted in the US and Europe.

Authorization in Turkey

The authorized Turkish therapeutic indications are stated as follows:

Therapeutic Indications

For recurrent or metastatic BRAF V600-positive malignant melanoma after progression on local treatment when further local therapy is unsuitable, with ECOG 0 or 1 and no previous RAF pathway inhibitor. Use alone or with cobimetinib is indicated until progression. 

It cannot be used after progression, alone or with other treatments.

Is Zelboraf Reimbursed?

SGK covers use alone or with cobimetinib until progression in recurrent or metastatic BRAF V600-positive malignant melanoma after progression on local treatment when further local treatment is unsuitable, with ECOG 0 or 1 and no previous RAF pathway inhibitor.

Price: As of August 2025, the pharmacy retail price of Zelboraf 240mg tablets is 27,295.25 ₺.

Zelboraf on the Off-Label List Usable Without Additional TİTCK Approval

Stage IV Malignant Melanoma: Appropriate as 1st-line treatment in BRAF V600-mutated disease.

Resistance Mechanisms

Although effective in BRAF-V600-mutated cells, cancer cells may develop resistance over time through:

• NRAS Mutations:
  • NRAS mutations may reactivate MAPK through alternative routes, reducing BRAF inhibitor effects.
• MEK1 and MEK2 Mutations:
  • Mutations in MEK1 and MEK2 within MAPK signaling can overactivate the pathway, defeating BRAF inhibition and sustaining growth.
• Direct MAPK Activation:
  • MAP2K1 (MEK1) and MAP2K2 (MEK2) mutations may activate MAPK independently of RAF, bypassing the targeted pathway and allowing cancer growth.
• Alternative Signaling:
  • Cells may evade treatment by activating c-Met, FGFR, EGFR, or PI3K/Akt pathways that support growth and survival.
• Ras/Raf Reactivation:
  • Additional KRAS, NRAS, or BRAF mutations can reactivate Ras/Raf and reduce effectiveness.
• BRAF Amplification:
  • Increasing BRAF copy number raises the amount of target protein. Excess protein can limit Zelboraf's effect.
• Loss of Tumor Suppressor Genes:
  • Loss of genes such as stromal antigen 2 (STAG2) and STAG3 contributes to uncontrolled growth and resistance.

Pharmacokinetic Properties

• Absorption
  • Oral bioavailability is approximately 58%.
  • Absorption is rapid and may be affected by food. High-fat meals may increase systemic exposure but do not affect terminal half-life.
  • Steady-state plasma levels are reached within 15-22 days.
    
    
• Distribution
  • Plasma protein binding exceeds 99%.
  • Steady-state blood levels take 2-3 weeks.
    
    
• Metabolism
  • Metabolized by hepatic microsomal CYP3A4 enzymes.
  • Eliminated through hepatobiliary excretion in feces (94%). Renal elimination is minor, accounting for only 1%.
  • Terminal half-life is approximately 57 hours.
    
    
• Dosage Range
  • Recommended dose: 960 mg orally twice daily.
  • Duration and dose may be adjusted according to clinical condition and tolerance.

Drug Interactions

• Increased Toxicity:
  • CYP3A4 inhibitors such as ketoconazole or erythromycin may slow metabolism and increase toxicity.
• Reduced Effectiveness:
  • CYP3A4 inducers such as rifampin, carbamazepine, or St. John's Wort may accelerate metabolism and reduce effectiveness.

Precautions 

• Skin Examinations:
  • Because cutaneous squamous cell cancer incidence increases, examine skin at baseline and every 2 months during treatment.
• Severe Skin Reactions:
  • Stop treatment for severe reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis.
• Photosensitivity:
  • Avoid sunlight exposure during treatment.
• Eye Reactions:
  • Ocular effects may include uveitis, iritis, and retinal vein occlusion.
• BRAF Testing:
  • Confirm BRAF-V600E using an FDA-approved test to determine eligibility for Zelboraf.
• Hepatic and Renal Impairment:
  • No adjustment is needed for mild or moderate liver and/or kidney impairment. Use caution in severe impairment.
• Pregnancy and Breastfeeding:
  • Zelboraf is pregnancy category D. Use is not recommended during pregnancy and it should not be used while breastfeeding.
• Monitoring:
  • Monitor electrolytes and QT regularly. Stop treatment if QTc >500 ms.
• Drug Interactions:
  • Use cautiously with CYP3A4 inhibitors or inducers, which may alter effectiveness and toxicity.

Side Effects 

• Skin Toxicity:
  • Cutaneous squamous cell carcinoma and keratoacanthoma, potentially developing within 7-8 weeks of starting treatment.
• Skin Reactions:
  • Severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
• Cardiac Toxicity:
  • QTc prolongation.
• Liver:
  • Increased bilirubin and ALT/AST.
• Photosensitivity:
  • Sensitivity to sunlight.
• Eye Reactions:
  • Uveitis, iritis, photophobia, and retinal vein occlusion.
• Fatigue:
  • Reported as a common effect during treatment.